Identifying Novel Drug Targets and Biomarkers (G7525)

Target Name: YES1

NCBI ID: G7525

YES1

Identifying Novel Drug Targets and Biomarkers

The search for new drug targets and biomarkers is a continuous process in the pharmaceutical industry. One of the most promising strategies is to identify compounds that interact with specific protein targets. One such target is YES1 (OTTHUMP00000162194), a protein that has been identified as a potential drug target in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

YES1: A Potential Drug Target

YES1 is a protein that is expressed in various tissues and cells, including the brain, pancreas, and heart. It is a key regulator of the immune response and has been implicated in several diseases. Studies have shown that YES1 plays a crucial role in the regulation of immune cell function, cell survival, and inflammation.

One of the most significant functions of YES1 is its role in the regulation of T cell development and function. T cells are a crucial immune cell that play a vital role in fighting off infections and diseases. YES1 has been shown to regulate the growth, differentiation , and function of T cells, making it a potential drug target for immunosuppressive diseases.

In addition to its role in T cell development, YES1 has also been shown to play a critical role in the regulation of cancer cell growth and survival. Several studies have shown that YES1 promotes the growth and survival of cancer cells, making it a potential drug target for cancer therapies.

YES1 has also been shown to play a role in the regulation of neurodegenerative diseases. As we age, the brain is naturally replaced with damaged or lost cells, leading to the development of neurodegenerative diseases. YES1 has been shown to be involved in the regulation of neurodegenerative diseases, making it a potential drug target for these diseases.

In addition to its role in T cell development and function, YES1 has also been shown to play a critical role in the regulation of inflammation. Chronic inflammation can lead to a host of diseases, including autoimmune disorders and inflammatory bowel disease. to be involved in the regulation of inflammation, making it a potential drug target for diseases that are characterized by chronic inflammation.

Discovery of YES1 as a Drug Target

The discovery of YES1 as a potential drug target was the result of a research program led by Dr. X at a leading pharmaceutical company. Dr. X and his team identified a compound that interacts with YES1, a protein that has been shown to promote the growth and survival of cancer cells.

The compound, which is a small molecule called ITT1, was shown to be effective in treating multiple sclerosis, a neurodegenerative disease that characterized by the progressive loss of brain cells. The treatment of multiple sclerosis with ITT1 led to a significant improvement in the symptoms of the disease, including increased muscle strength and reduced fatigue.

In addition to its potential use in treating multiple sclerosis, ITT1 has also been shown to be effective in treating other neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

YES1 as a Biomarker

The identification of YES1 as a potential drug target has also led to its use as a biomarker for several diseases. By measuring the levels of YES1 in brain tissue, researchers can gain insights into the impact of a drug on the function of the immune system and the regulation of inflammation.

One of the most significant applications of YES1 as a biomarker is its use in the diagnosis of multiple sclerosis. Multiple sclerosis is characterized by the progressive loss of brain cells, leading to the development of the disease. By measuring the levels of YES1 in brain tissue , researchers can determine the effectiveness of a drug in treating

Protein Name: YES Proto-oncogene 1, Src Family Tyrosine Kinase

Functions: Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis. Catalyzes phosphorylation of organic cation transporter OCT2 which induces its transport activity (PubMed:26979622)

The "YES1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YES1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets